Journey biosciences and cardinal health optifreight® logistics collaborate to improve long-term diabetes care

Lebanon, n.h., oct. 14, 2021 /prnewswire/ -- journey biosciences, inc., a biotechnology company with an innovative proactive diagnostic screening technology for high risk kidney complications, including diabetic kidney disease (dkd), today announced a collaboration with cardinal health (nyse: cah) optifreight® logistics that will increase control and visibility across every transportation modality.
CAH Ratings Summary
CAH Quant Ranking